CHELSEY RIDENOUR: Open Payments
NPI 1275040669 · NEWTON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$412 in 13 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $412
Food & beverage: $412
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 1 | $121 |
| Alexion Pharmaceuticals, Inc. | 3 | $82 |
| Chiesi USA, Inc. | 2 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Lilly USA, LLC | 1 | $27 |
| Genentech USA, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| CSL Behring | 1 | $15 |
Products named: ULTOMIRIS, ELFABRIO, ENTYVIO, KISUNLA, Ocrevus Zunovo, VYEPTI, GAMMAGARD, Leqembi.
Industry payments across AL — which companies pay providers there.
